Showing 6121-6130 of 9845 results for "".
- DermWire Exclusive: Inside the COVID-19 Outbreak in Italy with Dr. Sebastiano Recalcatihttps://practicaldermatology.com/news/dermwire-covid-19-exclusive-inside-the-outbreak-in-italy-with-sebastiano-recalcati/2460352/Dr. Sebastiano Recalcati, a dermatologist in Lombardy, Italy, was one of many doctors called to the frontlines in that country when COVID-19 ravaged the region. He published his observations in the Journal
- San Diego Dermatology Symposium Reschedules to Septemberhttps://practicaldermatology.com/news/san-diego-dermatology-symposium-reschedules-to-september/2460350/San Diego Dermatology Symposium will be held September 11-13, 2020, a shift from its original date. "The safety of our attendees, faculty, and exhibitors is our utmost priority, and we have been closely monitoring guidance from federal, state and local governments, as well as the World Healt
- Industry Responds to COVID-19: Henry Schein Medical, PCA Skinhttps://practicaldermatology.com/news/industry-responds-to-covid-19-henry-schein-medical-pca-skin/2460344/Henry Schein Medical. Henry Schein Medical is making
- Lessons from Italy: Understanding and Recognizing Potential Skin Manifestations in COVID-19https://practicaldermatology.com/news/lessons-from-italy-understanding-and-recognizing-potential-skin-manifestations-in-covid-10-1/2460340/Italian dermatologists report that about 20 percent of COVID-19 patients may develop skin manifestations including red rashes. Their findings appear in Journal of the European Academy of Dermatology Venereology. The researchers looked at skin in 148 COVID-19 patients
- Dupixent Significantly Improves Severe AD in Childrenhttps://practicaldermatology.com/news/dupixent-significantly-improves-severe-ad-in-children/2460338/Dupixent showed significant improvement in severe atopic dermatitis (AD) for children aged 6 to 11 Years, according to a Phase 3 study. In the trial, Dupixent combined with standard-of-care topical corticosteroids (TCS) significantly improved disease signs, symptoms and health-related q
- CSF Live Virtual Meeting to Assess SBA Loans: Tonighthttps://practicaldermatology.com/news/csf-live-virtual-meeting-to-access-sba-loans-tonight/2460334/As dermatology business owners’ heads are swimming trying to figure out the SBA loan to keep afloat during the COVID crisis, CSF, along with George Hruza, MD, immediate past-president of the AAD, and Greg Morganroth, MD, CEO and Founder of California Skin Institute, will discuss the ins-and
- Novartis Terminates Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo in Mutual Agreementhttps://practicaldermatology.com/news/novartis-terminates-sale-of-sandoz-us-generic-oral-solids-dermatology-portfolio-to-aurobindo-in-mutual-agreement/2460332/In a mutual agreement with Aurobindo Pharma USA Inc., Novartis has terminated the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within ant
- Tonight: DEF Webinar Series Kicks Off to Explore COVID-19 Impact on PAs, NPshttps://practicaldermatology.com/news/tonight-def-webinar-series-kicks-off-to-explore-covid-19-impact-on-pas-nps/2460331/Dermatology Education Foundation (DEF) tonight launches a new weekly video series that will focus on the impact of the COVID-19 crisis on dermatology NPs and PAs. Noting that this pandemic presents unprecedented personal and professional hardships and challenges to all practices, DEF ur
- Telehealth Webinar from Cosmetic Surgery Forum Explores Best Practiceshttps://practicaldermatology.com/news/telehealth-webinar-available-from-cosmetic-surgery-forum/2460325/As dermatologists deal with the evolving COVID-19 crisis, they are increasingly searching for guidance on the proper use of telemedicine. Joel Schlessinger, MD, Founder of Cosmetic Surgery Forum, brought together George Hruza, MD, past president of the AAD, and Antoanella Calame, MD, founder of t
- Evolve BioSystems and Janssen to Study the Impact of B. infantis EVC001 for AD Prevention in Infantshttps://practicaldermatology.com/news/evolve-biosystems-and-janssen-to-study-the-impact-of-b-infantis-evc001-for-ad-prevention-in-infants/2460324/Evolve BioSystems, Inc. and Janssen Research & Development, LLC, are partnering to conduct a study looking at the potential role of B. infantis EVC001 in preventing early childhood atopic dermatitis (AD). The study will assess the effects of introducing a specific gut